Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) has provided an announcement.
Raily Aesthetic Medicine International Holdings Limited has issued a profit warning, indicating an expected revenue of approximately RMB199 million and a loss of around RMB59 million for the year ending December 31, 2024. The continued loss is attributed to several factors, including the cessation of distribution for e-PTFE facial implants in the PRC, increased share option expenses, and heightened investment in research and development activities. The company’s financial results are based on unaudited management accounts and are subject to adjustments.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited operates in the aesthetic medicine industry, focusing on the development and distribution of medical equipment products. The company has been involved in research and development activities, particularly through its subsidiary Suzhou Ruiquan Biosciences Co., Ltd.
YTD Price Performance: 8.41%
Average Trading Volume: 341,340
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$64.62M
Find detailed analytics on 2135 stock on TipRanks’ Stock Analysis page.